What does hematemesis in cirrhosis indicate?

Jun 01, 2022 Source: Cainiu Health
Dr. Jin Zhongkui
Introduction
Hematemesis in patients with cirrhosis is most commonly caused by gastric varices—dilated veins at the gastric fundus—that rupture and bleed due to the underlying disease. As cirrhosis progresses, inflammatory cells and necrotic collagen continue to accumulate within the liver. Concurrently, structural alterations occur in the local hepatic architecture, potentially leading to increased portal venous pressure and subsequent bleeding.

When patients with liver disease experience hematemesis (vomiting blood), the condition may be quite serious. In fact, cirrhosis commonly leads to ascites and other complications, and tends to progress progressively. Timely and effective treatment is essential; otherwise, disease progression may become life-threatening and delay appropriate management. So, what exactly is hematemesis in cirrhosis?

       What Causes Hematemesis in Cirrhosis?

       Hematemesis in cirrhotic patients most frequently results from gastric varices—dilated veins at the gastric fundus—caused by portal hypertension secondary to liver disease. As cirrhosis advances, inflammatory cells and necrotic collagen progressively accumulate within the liver, while structural alterations occur in the hepatic architecture. These changes can lead to increased portal venous pressure and subsequent variceal rupture and bleeding. Additionally, patients may have coexisting gastric disorders; when gastric ulcers or other gastric pathologies occur alongside cirrhosis, declining immune function and impaired nutrient absorption may further contribute to hematemesis.

       Initial management of cirrhosis-related hematemesis should focus on establishing reliable intravenous access to rapidly expand intravascular volume. Hemostasis can be achieved using blood products or pharmacologic agents (e.g., vasoactive drugs). Endoscopic interventions—including endoscopic variceal sclerotherapy (EVS) and endoscopic variceal ligation (EVL)—are also recommended and should be performed at qualified medical centers. If endoscopic therapy fails or is contraindicated, balloon tamponade using a Sengstaken–Blakemore tube remains an effective temporizing measure. For patients with severe, refractory bleeding who are not surgical candidates or are awaiting liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS) may be employed as an emergency intervention—though it carries a significant risk of precipitating hepatic encephalopathy.

       During treatment, patients are advised to rest adequately and avoid raw, cold, or spicy foods. We hope this information proves helpful.